Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SV101
- Development stage
- Preclinical
- Lead developer
- Sysvax
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SV101 is a preclinical vaccine candidate developed by Sysvax for the prevention and treatment of tuberculosis (TB). It is designed using Sysvax's proprietary vaccine development platform, which focuses on identifying and expressing recombinant antigens to elicit a robust immune response against *Mycobacterium tuberculosis*. As a recombinant protein-based vaccine, SV101 aims to provide both prophylactic protection against initial infection and therapeutic benefits for individuals already infected with the pathogen. The candidate is currently undergoing preclinical evaluation to assess its safety and immunogenicity profile.
- Other names
- Sysvax tuberculosis vaccine
Beyond the preview
Go deeper on SV101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SV101.